For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
Thymalin is a polypeptide complex extracted from the thymus glands of young calves, developed by Professors Morozov and Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology beginning in the 1970s. Unlike the synthetic single-sequence Khavinson bioregulators (Epithalon, Pinealon, Vesugen, Pancragen), Thymalin is a multi-component preparation containing short peptides including the dipeptides EW (Glu-Trp, also known as Thymogen) and KE (Lys-Glu, also known as Vilon). The most significant human clinical finding is the indexed Khavinson and Morozov (2002, 2003) long-term observational study in 266 elderly persons (over 60 years), followed 6 to 8 years, which reported a 2.0 to 2.1-fold mortality decrease in Thymalin-treated patients and a 4.1-fold decrease in the group receiving Thymalin combined with Epithalamin annually over 6 years. Thymalin is also the only Khavinson bioregulator with approved Russian pharmaceutical status, with a COVID-19 PMC study in n=36 elderly patients providing the most recent indexed human data.
Thymalin is structurally distinct from every other compound profiled in this series. It is not a single defined synthetic peptide with a known sequence. It is a polypeptide complex, a reproducible mixture of low-molecular-weight peptides extracted from bovine thymus tissue by mild acid extraction and ultrafiltration. Its active components, identified by mass spectrometry and HPLC in published work (Zhurkovich et al. 2020, cited in PMC review), include the dipeptides EW (Glu-Trp, also called Thymogen) and KE (Lys-Glu, also called Vilon) and the tripeptide EDP (also called Crystagen). EW/Thymogen was separately registered as a drug in Russia in 1990. The relationship between Thymalin as a mixture and its individual active components is now well characterized.
The human longevity data in the landmark 266-patient study are extraordinary by any standard: 2.0 to 2.1-fold mortality reduction over 6 to 8 years in Thymalin-treated elderly patients compared to controls, rising to 4.1-fold reduction in those receiving Thymalin plus Epithalamin annually for 6 years. These numbers, if valid, would represent the most impactful longevity intervention in human medicine history. The critical limitations are equally significant: the study was not randomized, not blinded, conducted over the same period by the developers of the compound, and published in Advances in Gerontology (a Russian journal) and Neuroendocrinology Letters (a small international journal), not a major peer-reviewed clinical trial journal. No independent Western center has replicated these findings. The study design does not meet modern randomized controlled trial standards. These limitations must be stated clearly and prominently: the mortality data are a directional signal from an observational study, not validated clinical efficacy.
Thymalin has Russian pharmaceutical approval (LS-000267) and has been used clinically in Russia and Eastern Europe for over 40 years across a range of immune-related and infectious indications. This regulatory status is meaningful but not equivalent to Western regulatory approval, which requires Phase 3 RCT evidence.
Thymalin is not a synthetic peptide available from research vendors with defined purity. It is a biological pharmaceutical extract. Products sold by research vendors as "Thymalin" may or may not contain the same compositional profile as the registered Russian pharmaceutical preparation. This is a critical supply chain distinction that buyers should understand.
Thymalin was the first peptide bioregulator developed by the Morozov-Khavinson research program. The original work began at the Military Medical Academy in Leningrad in the early 1970s, when Professors Vyacheslav Morozov and Vladimir Khavinson developed a technology for extracting polypeptide complexes from organ tissues of young animals using mild acid hydrolysis and ultrafiltration.
The founding hypothesis was that the thymus gland, which governs T-cell maturation and is central to adaptive immunity, declines in function with age through involution. Thymic involution begins around puberty and is largely complete by age 50 to 60. This decline contributes directly to immunosenescence, the age-related deterioration of immune competence that increases susceptibility to infection, cancer, and autoimmune disease. Thymalin was designed to partially restore thymic-driven immune function by supplying the signaling peptides that the aging, involuted thymus no longer produces in sufficient quantity.
The active component analysis has been progressively refined over five decades. The dipeptide EW (Glu-Trp) was isolated from Thymalin by reversed-phase high-performance liquid chromatography in the 1980s and subsequently synthesized and registered as the drug Thymogen (Russian Ministry of Health Registration Certificate PN002408/01, June 2009). Thymogen was found to activate T-cell differentiation, induce changes in cyclic nucleotide levels, and enhance neutrophil chemotaxis and phagocytosis. Mass spectrometry and HPLC characterization published in 2020 (Zhurkovich et al.) confirmed that Thymalin also contains the dipeptide KE (Lys-Glu, Vilon) and the tripeptide EDP (Crystagen).
The historical clinical context is important: Thymalin was developed in the Soviet military medicine system and was used clinically in the USSR from the early 1980s. It received formal Russian pharmaceutical registration in 2010 (LS-000267), formalizing decades of clinical use. It has documented clinical application across acute and chronic viral and bacterial infections, immunodeficiency states, post-chemotherapy or post-radiation immune suppression, and age-related immune decline. The COVID-19 pandemic produced the most recent indexed clinical data: a 2021 PMC-indexed study in n=36 elderly patients with severe COVID-19 at Chita State Medical Academy.
Thymalin acts through multiple convergent mechanisms, reflecting its multi-component composition. The primary and best-characterized action is T-cell maturation restoration.
The core immunological mechanism: Thymalin restores the number and ratio of T and B lymphocytes, their subpopulations, their functional activity, and enhances phagocytosis. Specifically, it reverses age-related depletion of CD4-positive T helper cells and CD8-positive cytotoxic T cells, restores CD4:CD8 ratio, enhances natural killer cell activity, and normalizes B-cell function. These effects have been documented in both animal models and the human clinical studies. The mechanistic basis is restoration of thymic peptide signaling that normally drives T-cell precursor differentiation and maturation in the thymus, a process that declines dramatically as the thymus involutes with age.
At the molecular level, the active components EW and KE interact with DNA through chromatin binding, following the general Khavinson bioregulator framework. The 2023 IJMS paper by Linkova, Khavinson et al. characterizes EW as: reducing angiotensin-induced vasoconstriction, preserving endothelium-dependent vascular relaxation by inhibiting ACE2 (which is also the target protein of SARS-CoV-2), modulating inflammatory responses including IL-6, TNF-alpha, and NF-kB pathways. KE stimulates cellular immunity and nonspecific resistance, exerting activating effects on macrophages, blood lymphocytes, thymocytes, and neutrophils, and induces expression of CD4 and CD5 molecules on thymus cells.
The hematopoietic stem cell differentiation pathway is also proposed: Thymalin stimulates hematopoietic stem cells in the bone marrow, enhancing production of immune mediator precursors. This pathway becomes particularly relevant in the context of COVID-19-related lymphopenia, where the depletion of circulating lymphocytes represents a functional failure that Thymalin may partially reverse by accelerating lymphocyte replenishment from stem cell precursors.
The neuroendocrine axis connection is documented in the 6 to 8 year observational study: Thymalin administration in elderly persons improved not only immune indices but also endocrine and cardiovascular parameters, consistent with the bidirectional pineal-thymic axis proposed by Khavinson in which thymic peptides influence melatonin secretion patterns and pineal peptides influence thymic function. This systemic rather than organ-specific effect is consistent with the multi-component nature of the preparation.
The 266-person study (elderly persons over 60 years) was conducted jointly by the St. Petersburg Institute of Bioregulation and Gerontology and the Institute of Gerontology of the Ukrainian Academy of Medical Sciences in Kiev. Participants received Thymalin (thymic polypeptide), Epithalamin (pineal polypeptide), both together, or no treatment (control). The bioregulators were administered by intramuscular injection at 10 mg daily for 10 days per course. Treatment was applied during the first 2 to 3 years of the 6 to 8 year observation period.
The primary mortality findings: 2.0 to 2.1-fold mortality decrease in Thymalin-treated patients compared to control; 1.6 to 1.8-fold decrease in Epithalamin-treated group; 2.5-fold decrease in patients receiving Thymalin plus Epithalamin. In a separate subcohort receiving Thymalin combined with Epithalamin annually for 6 years, mortality decreased 4.1-fold compared to control.
Secondary findings: 2.0 to 2.4-fold decrease in acute respiratory disease incidence; reduced clinical manifestations of ischemic heart disease, hypertension, deforming osteoarthrosis, and osteoporosis compared to control.
The 2003 English publication in Neuroendocrinology Letters describes a double-blind screening component for immunological endpoints within the 266-person study, but the long-term observational mortality tracking was not double-blind in design. The control group was not placebo-treated in a blinded manner. Both institutions conducting the study are affiliated with or closely associated with the Khavinson bioregulator research program. No independent replication of these mortality findings has been published in a Western peer-reviewed trial.
The 266-patient long-term study is the most extraordinary human finding in the entire Khavinson bioregulator literature and among the most extraordinary claims in gerontology broadly: a 2.0-fold mortality reduction maintained over years in a defined elderly population. The claim is extraordinary enough that the absence of independent Western replication over 20-plus years is editorially significant. The study is not a randomized controlled trial; it does not meet the evidentiary standard required for clinical recommendations. The mortality signal is directionally real or the study is fundamentally flawed; either interpretation deserves independent investigation that has not happened.
In the 2021 Kuznik et al. PMC study, elderly patients with severe COVID-19 manifesting progressive respiratory failure and cytokine storm signs (elevated D-dimer, C-reactive protein, LDH, IL-6, low platelets, decreased fibrinogen, lymphopenia, coagulopathy, lung tissue damage) received Thymalin added to standard therapy. The n=36 Thymalin group showed more rapid clinical improvement, higher proportions of recovery from lymphopenia, faster normalization of C-reactive protein, and recovery in blood levels of platelets/lymphocytes ratio, CD4-positive, CD3-positive HLA-DR-positive, B-cell, and NK-cell subpopulations compared to the standard therapy group.
A separate 2020 case report (Lukyanov, Kuznik, Shapovalov, Khavinson, et al., International Journal of Immunology and Immunotherapy) described a single patient with severe bilateral SARS-CoV-2 pneumonia who did not respond to lopinavir/ritonavir plus hydroxychloroquine but showed impressive clinical and laboratory improvement after Thymalin was added. The case report group noted that a randomized controlled trial of Thymalin in COVID-19 was being planned at the time of publication.
The COVID-19 findings are consistent with Thymalin's known mechanism: COVID-19 causes profound lymphopenia and T-cell exhaustion, particularly in elderly patients whose immune reserves are already depleted by age-related thymic involution. Thymalin's ability to restore T-cell subpopulations and reduce inflammatory burden directly addresses the immunological failure pattern of severe COVID-19.
The COVID-19 data are the most recent indexed human evidence for Thymalin in a defined acute disease setting with objective immunological endpoints. The n=36 PMC-indexed study provides more methodological detail than the mortality study but is still not a randomized controlled trial. The biological plausibility is high: COVID-19 in the elderly specifically involves T-cell depletion and thymic reserve deficiency that Thymalin is designed to address. These findings justify a randomized trial that, as of 2026, has not been reported in indexed literature.
Thymalin has documented clinical use in Russia and Eastern Europe across a broad range of immune-related indications. The indexed summary literature (Morozov and Khavinson 1997, cited in PMC review; Kuznik et al. 2016) documents successful use as adjunct therapy in influenza, viral hepatitis B and C, herpes simplex, HIV, lung abscess, pulmonary disease, sepsis, and acute respiratory distress syndrome. In all these settings, Thymalin is used as an immunomodulator to restore T-cell function compromised by acute infection, not as a primary antiviral or antibacterial agent.
The 1997 Morozov and Khavinson paper in International Journal of Immunopharmacology is one of the few Thymalin publications in an international immunology journal with Western editorial standards. It characterized the comparative immunological mechanisms of Thymalin and its synthetic derived fractions, documenting T-cell differentiation activation, changes in intracellular cyclic nucleotide composition, induction of IL-2 and interferon excretion from blood lymphocytes, and neutrophil chemotaxis and phagocytosis enhancement.
The blood coagulation normalization effect is a separate documented property: Thymalin (and Thymogen) administration in patients with pneumonia and various viral infectious diseases was accompanied by normalization of coagulation and fibrinolytic activity of blood plasma proteins. This anticoagulant-compatible effect becomes particularly relevant in COVID-19, where coagulopathy is a major cause of mortality.
The infectious disease immunomodulation data represent the largest body of Thymalin clinical experience but most exists as Russian-language observational literature without Western RCT design. The 1997 International Journal of Immunopharmacology paper is the strongest Western-facing mechanistic characterization. The blood coagulation normalization effect is a consistently reported finding across multiple indications that adds clinical utility beyond pure immune cell counts.
The 2020 characterization work (Zhurkovich et al., cited in the 2021 PMC Springer review) definitively identified the active peptide components of Thymalin using modern mass spectrometry and HPLC: the dipeptides EW (Glu-Trp, also known as Thymogen) and KE (Lys-Glu, also known as Vilon) and the tripeptide EDP (Crystagen). All three have high biological activity.
The 2023 IJMS paper by Linkova, Khavinson et al. performed molecular modeling and docking analysis of EW and KE against COVID-19 pathogenesis targets. EW was found to: inhibit angiotensin-induced vasoconstriction; preserve endothelium-dependent vascular relaxation by modulating ACE2; reduce inflammatory responses involving IL-6, TNF-alpha, and NF-kB signaling; and bind to DNA regions controlling immune response genes. KE stimulates cellular immunity and nonspecific resistance, activates macrophages, blood lymphocytes, thymocytes, and neutrophils, and induces CD4 and CD5 expression on thymic cells.
The characterization work is important for Thymalin users because it establishes that the clinical effects of the polypeptide complex are largely attributable to specific, well-characterized short peptides. EW (Thymogen) is itself a registered drug with independent clinical data including registered use in acute and chronic viral and bacterial respiratory disease. This means Thymalin's efficacy is not dependent on undefined mysterious components but on identified peptide fractions that also have independent supporting evidence.
The active component analysis resolves a fundamental question about Thymalin: what is actually doing the work? The identification of EW, KE, and EDP as the primary active fractions by modern analytical methods is scientifically clarifying. It means Thymalin's clinical effects are largely predictable from the known biology of these components. The 2023 IJMS paper's ACE2 inhibition finding for EW is mechanistically interesting in the COVID-19 context and provides a receptor-level explanation for some of the antiviral immune effects. All characterization data are from in vitro and molecular modeling; the link to clinical outcomes is mechanistic inference.
The Anisimov, Khavinson, Morozov 2001 Biogerontology paper tested the isolated EW dipeptide (the primary active fraction of Thymalin, marketed as Thymogen) in female outbred rats at 5 micrograms per rat subcutaneously 5 times per week for 12 months from age 5 months. The treated group (n=44) showed slower spontaneous tumor development, increased T-cell differentiation activity, T-cell recognition of peptide-MHC complexes, improved cyclic nucleotide intracellular composition, and activated neutrophilic chemotaxis and phagocytosis compared to saline controls (n=32). This study is particularly relevant because it used the isolated active fraction rather than the whole complex, providing cleaner mechanistic attribution.
The oncology-adjacent literature for Thymalin as a complex includes post-surgical lung infection management (where T-cell and immune restoration accelerates recovery from infection following thoracic surgery) and the general clinical use in post-chemotherapy or post-radiation immune suppression, which is documented in the regulatory prescribing context for the Russian pharmaceutical preparation.
The mechanism for cancer-relevant effects is immune surveillance: Thymalin's restoration of NK cell activity and cytotoxic T-cell function should theoretically enhance the immune system's ability to detect and eliminate nascent tumor cells. This is a plausible mechanistic claim but the clinical cancer prevention data are entirely from observational contexts and animal models, not from randomized cancer prevention trials.
The EW/Thymogen cancer inhibition data in rats provide preclinical support for a cancer immune surveillance mechanism. The post-chemotherapy immune restoration use is clinically rational given Thymalin's established immunorestorative profile. The key limitation is that immune restoration in the context of existing cancer treatment is fundamentally different from cancer prevention. No randomized cancer prevention or treatment outcome trial with Thymalin has been published.
Original Khavinson protocol: 5-10mg/day for 5-10 days.
Thymalin is a registered Russian pharmaceutical with a standard dosing protocol: 10 mg IM daily for 10 days (100 mg per course). This dose is consistent across all published human clinical studies and the regulatory prescribing information (LS-000267). The 6 to 8 year mortality study used this dose for treatment during the first 2 to 3 years. The 6-year annual subcohort used this dose once yearly. The COVID-19 study (n=36) used this registered pharmaceutical dose. humanDataAvailable is true because the standard dose is documented in indexed human studies. The 5 mg daily dose option reflects some researchers using half the standard course dose for preventive protocols, without a separate published dose-finding rationale.
Thymalin is fundamentally different from every other compound profiled in this series in three ways: it is a polypeptide complex (not a single defined synthetic peptide), it has Russian pharmaceutical approval (not just research compound status), and it has 40-plus years of active clinical use rather than purely experimental or observational data. The closest profiled compound is Thymosin Alpha-1 (Tα1), which is also thymus-derived but is a single defined 28-amino-acid protein with substantially more Western RCT data, FDA Orphan Drug status in the USA, and regulatory approval in multiple countries for hepatitis B and C, and which has been studied in COVID-19 with published Phase 3 data from China. Tα1 and Thymalin have different mechanisms, different molecular structures, and different evidence profiles; they should not be treated as interchangeable thymic peptides. Thymalin's active fraction Thymogen (EW, Glu-Trp) has independent Russian pharmaceutical registration and overlapping evidence, meaning the profile of Thymalin as a whole is partially explained by its known active components.
Thymalin has the most extensive human safety record of any compound in this series by a significant margin: 40-plus years of clinical use in Russia and Eastern Europe across diverse populations and indications. The Russian pharmaceutical registration (LS-000267) reflects decades of post-market experience. The available literature uniformly reports Thymalin as having no significant adverse effects across its clinical applications.
The PMC-indexed COVID-19 study (Kuznik et al. 2021) in n=36 elderly patients with severe COVID-19 specifically noted no adverse effects in the Thymalin group. The 266-patient 6-8 year observational study reported no adverse effects. Multiple infection and sepsis studies have described a favorable safety profile.
A specific safety consideration for Thymalin is its immunomodulatory profile. Because Thymalin restores T-cell activity, it requires caution in: (1) patients with active autoimmune disease, where increased T-cell activation could worsen inflammatory pathology; (2) organ transplant recipients receiving immunosuppressive therapy, where enhanced T-cell activity could drive graft rejection; (3) patients with lymphoproliferative disorders, where T-cell stimulation could theoretically promote clonal expansion. None of these are reported adverse events; they are pharmacological precautions based on mechanism.
Because Thymalin is a biological extract rather than a synthetic defined compound, there is also a theoretical risk of immune sensitization reactions with repeated exposure to bovine proteins. This has not been a reported clinical issue in the Russian literature, but it is a consideration that would not apply to the synthetic dipeptide fractions (Thymogen, Vilon).
No mutagenicity, carcinogenicity, or reproductive toxicity has been reported in published Thymalin animal or clinical data. The anti-tumor immune enhancement effects seen in long-term studies are consistent with immune surveillance enhancement rather than oncogenesis.
Thymalin is the oldest, most clinically used, and most distinctively evidenced compound in this entire series. It is also the hardest to evaluate fairly because its evidence profile is simultaneously its greatest strength and its greatest weakness.
The 266-patient long-term mortality study is the most important finding and the most impossible to evaluate without replication. A 2.0-fold mortality decrease, rising to 4.1-fold with annual combined treatment, maintained over 6 to 8 years in elderly patients is an extraordinary claim that would, if validated, represent the most impactful longevity intervention in clinical medicine. The study was not randomized, was not blinded for the long-term mortality endpoint, and was conducted by the developers of the compound. The Neuroendocrinology Letters paper has been indexed in PubMed since 2003. No independent center has attempted to replicate these mortality findings in the 20-plus years since publication. This silence is itself informative: either the findings are not considered credible enough to warrant replication investment, or the gerontology research infrastructure in Russia has not generated the trial sponsorship to do so, or the effect is real but Western researchers remain unaware of it. None of these explanations is definitively correct.
What is unambiguous about Thymalin: it has 40-plus years of clinical use in Russia with regulatory approval; its active components (EW, KE, EDP) are well-characterized and have independent pharmacological data; the COVID-19 findings from 2021 provide the most recent indexed objective clinical data; the biological rationale for thymic immune restoration in the elderly is scientifically sound; and Thymalin's safety profile is the cleanest in this series, validated by decades of widespread clinical use.
What remains unambiguous as a gap: no randomized controlled trial has been published in indexed Western literature. The immunosenescence hypothesis that justifies Thymalin's use is widely accepted; the clinical evidence that Thymalin corrects it with meaningful outcomes in aged humans remains unvalidated by the standards of evidence-based medicine as practiced outside Russia.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use